CD19 and diffuse large B-cell lymphoma: New anti-CD19 antibody tafasitamab and new antibody–drug conjugates, anti-CD79B polatuzumab vedotin and anti-CD19 loncastuximab tesirine, were approved for patients with relapsed or refractory (R/R) DLBCL [7,8].